BBOT vs BCTX

BridgeBio Oncology Therapeutics vs BriaCell Therapeutics Corp. — Valuation Comparison 2026

BBOT

Biotechnology
BridgeBio Oncology Therapeutics
Quality
6.2
out of 10
Value Trap
Price
$8.84
Last close
Models
9/13
Active
VS

BCTX

Biotechnology
BriaCell Therapeutics Corp.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$3.58
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BBOT Fair ValueBBOT Upside BCTX Fair ValueBCTX Upside
Bayesian DCF Intrinsic $2.70 -69.5% $3.26 -8.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.10 -98.9% $0.38 -91.0%
Dynamic NAV Asset-Based $3.92 -55.6% $7.83 +118.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBOT vs BCTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBOT vs BCTX — Which Stock Is More Undervalued?

BBOT scores higher with a 6.2/10 quality rating vs BCTX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Oncology Therapeutics (BBOT) and BriaCell Therapeutics Corp. (BCTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBOT currently trades at $8.84 with a QOC of 6.2/10, while BCTX trades at $3.58 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).